Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

People with diabetes who took medications like Ozempic or Wegovy had a lower risk of serious blood clots compared to people ...

Ghana has become the first country in Africa to take stock of a highly-sort after, efficient drug for Type 2 diabetes patients, Januvia. This was announced by the President of the National ...

[31] Double-blind, placebo-controlled studies on the safety and efficacy of sitagliptin have been conducted with patients with Type 2 diabetes. Mean age was 55 and participants were of varying ...

Merck described Januvia as “an important advance for adults with type 2 diabetes” and added that innovations like sitagliptin ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...